IDEXX LaboratoriesFRA:IX1 +3.16%96 Return-on-Tangible-Equity is 105.72% as of Mar. 2026, which is 48% below its 10-year median of 202.59. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €551.02 (Modestly Undervalued). Among 192 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 85.94% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. IDEXX Laboratories's annualized net income for the quarter that ended in Mar. 2026 was €963 Mil. IDEXX Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €911 Mil. Therefore, IDEXX Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 105.72%.
The historical rank and industry rank for IDEXX Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
FRA:IX1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 84.05 Med: 202.59 Max: 539.98
Current: 108.93
During the past 13 years, IDEXX Laboratories's highest Return-on-Tangible-Equity was 539.98%. The lowest was 84.05%. And the median was 202.59%.
FRA:IX1's Return-on-Tangible-Equity is ranked better than 85.94% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs FRA:IX1: 108.93
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
IDEXX Laboratories Return-on-Tangible-Equity Related Terms
IDEXX Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IX1 vs A, NTRA, WAT: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, IDEXX Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 105.72% mean?
IDEXX Laboratories (FRA:IX1) has a Return-on-Tangible-Equity of 105.72% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IDEXX Laboratories and its competitors. This is 48% below median its historical median of 202.59. Over the past decade, IDEXX Laboratories' Return-on-Tangible-Equity has ranged from 84.05 to 539.98. According to the industry distribution chart, IDEXX Laboratories ranks #27 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 14.1%.
Is IDEXX Laboratories' Return-on-Tangible-Equity too high?
IDEXX Laboratories' current Return-on-Tangible-Equity of 105.72% is 48% below median its 10-year median of 202.59. Over the past 10 years, this metric has ranged from a low of 84.05 to a high of 539.98. Based on the distribution chart, IDEXX Laboratories ranks #27 out of 192 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Return-on-Tangible-Equity compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #27 out of 192 companies for Return-on-Tangible-Equity. This places IDEXX Laboratories in the top 14% of its industry — outperforming the majority of peers. Historically, IDEXX Laboratories' own Return-on-Tangible-Equity has ranged from 84.05 to 539.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Return-on-Tangible-Equity is 105.72%, which is 48% below median its own 10-year median of 202.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €551.02, compared to a current price of €486.30 — trading 11.7% below its estimated fair value. The current Return-on-Tangible-Equity is 105.72%, which is 48% below median its 10-year median of 202.59. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Return-on-Tangible-Equity is 105.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €486.30 is trading 11.7% below its estimated GF Value™ of €551.02.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
Return-on-Tangible-Equity: 105.72% (48% below median its 10-year median of 202.59)
GF Value™: €551.02 vs. price of €486.30 (11.7% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
